http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017536398-A
Outgoing Links
Predicate | Object |
---|---|
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2077 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1682 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-146 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1652 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-141 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38 |
filingDate | 2015-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2017-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | JP-2017536398-A |
titleOfInvention | Anticancer composition |
abstract | The present invention relates to pharmaceutical formulations of ARN-509, which formulations are androgen receptor (AR) related diseases or conditions, specifically cancer, more specifically prostate cancer, such as, but not limited to, Castration-resistant prostate cancer, metastatic castration-resistant prostate cancer, chemotherapy-naïve metastatic castration-resistant prostate cancer, biochemically recurrent hormone-sensitive positive prostate cancer, or high-risk non-metastatic castration-resistant prostate cancer Can be administered to mammals, particularly humans. In one aspect, these formulations comprise a solid dispersion of ARN-509 and HPMCAS. In one aspect, a solid dispersion of ARN-509 and HPMCAS is obtainable by melt extruding a mixture comprising ARN-509 and HPMCAS followed by optionally grinding the melt extrusion mixture. Especially obtained. In one aspect, a solid dispersion of ARN-509 and HPMCAS is obtainable and particularly obtainable by spray drying a mixture comprising ARN-509 and HPMCAS in a suitable solvent. |
priorityDate | 2014-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 200.